KW-3357 + heparin

KW-3357 + heparin is a **combination therapy** consisting of recombinant antithrombin gamma (KW-3357) and **heparin**, intended for the **treatment of disseminated intravascular coagulation (DIC) and antithrombin III deficiency**. KW-3357 is a recombinant form of antithrombin produced using recombinant DNA and glycoengineering technology; it acts as a **thrombin inhibitor** and is classified as an anticoagulant/antithrombin. Heparin is a well-established anticoagulant that potentiates the inhibitory action of antithrombin on thrombin and factor Xa, further supporting anticoagulation. The combination therapy was designed to enhance antithrombin activity and provide effective management of hypercoagulable states, particularly acute DIC, and was the subject of multiple phase 3 trials initiated by Kyowa Kirin[1][2][3][4][5][6].

Brand names

Acoalan

Other names

antithrombin gammaantithrombin (human variant kw-3357)afucosylated antithrombinantithrombin gamma (genetical recombination)